JPMorgan Chase & Co. set a €97.00 ($115.48) price target on MorphoSys (ETR:MOR) in a research report released on Thursday. The firm currently has a buy rating on the stock.
Other equities analysts also recently issued reports about the stock. Berenberg Bank set a €85.00 ($101.19) price objective on shares of MorphoSys and gave the stock a buy rating in a report on Thursday, December 7th. Independent Research set a €93.00 ($110.71) price objective on shares of MorphoSys and gave the stock a buy rating in a report on Friday, December 1st. Goldman Sachs Group set a €80.00 ($95.24) price objective on shares of MorphoSys and gave the stock a neutral rating in a report on Monday, November 27th. Deutsche Bank set a €90.00 ($107.14) price objective on shares of MorphoSys and gave the stock a buy rating in a report on Wednesday, November 8th. Finally, Oddo Bhf set a €90.00 ($107.14) price target on shares of MorphoSys and gave the stock a buy rating in a report on Wednesday, November 8th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of €83.75 ($99.70).
Shares of MorphoSys (ETR:MOR) opened at €80.85 ($96.25) on Thursday. The company has a market cap of $2,380.00 and a price-to-earnings ratio of -27.41. MorphoSys has a one year low of €46.50 ($55.36) and a one year high of €83.83 ($99.80).
WARNING: “JPMorgan Chase & Co. Analysts Give MorphoSys (MOR) a €97.00 Price Target” was originally published by Equities Focus and is the property of of Equities Focus. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.equitiesfocus.com/2018/01/08/jpmorgan-chase-97-00-price-target.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.